COVID-19 subvariant Omicron XE emerges in Australia

By Rich Klein
Health workers attend a COVID-19 testing site in Brisbane, Australia, in January. Photo by Jono Searle/EPA-EFE
Health workers attend a COVID-19 testing site in Brisbane, Australia, in January. Photo by Jono Searle/EPA-EFE

April 15 (UPI) -- A new COVID-19 subvariant known as Omicron XE has emerged in Australia, officials confirmed Friday.

New South Wales health authorities said that the first reported case was confirmed when a traveler returned from overseas last week.


XE is a combination of previous variants, BA.1 and BA.2, Dr. Maria Van Kerkhove of the World Health Organization said in a YouTube video this week about the development.

Australian authorities on Monday lifted restrictions on travelers that required mandatory negative COVID-19 tests prior to arriving in the country.

RELATED New variants mean COVID-19 poses continued threat, experts say

In mid-January, Britain became the first country to detect XE and has since recorded more than 1,000 cases. XE has also shown up Thailand, Canada, Israel and India.

Japan said Tuesday that it also confirmed its first XE case.

The United States has not officially reported any XE cases as of Friday.

RELATED COVID-19 worldwide down to million cases, 3,500 deaths daily

"We may be done with the virus, but the virus isn't done with us," public health expert Michael T. Osterholm said this week. "It is clear with the emergence of new variants that this virus isn't going to go away and become dormant anytime soon."


Osterholm is a professor of public health at the University of Minnesota in Minneapolis and a former adviser to the Biden administration.

Earlier this month, one expert said there's too much "hype" attached to the new variants.

RELATED Scientists unsure how new COVID-19 variant -- Omicron XE -- behaves, responds to vaccines

"I find it very disappointing and unhelpful how much people are hyping these variants," Jeremy Kamil, associate professor of microbiology and immunology at Louisiana State University Health Shreveport, said. "They are scientifically interesting but remain largely a curiosity. "These are not at all likely to pose a special or unique threat and we should not treat them as if they do."

In the United States, the Food and Drug Administration gave emergency use authorization for the first COVID-19 test by a breathalyzer.

RELATED FDA grants emergency use authorization to COVID-19 Breathalyzer test

RELATED Adults at higher risk for vision problems after COVID-19, study finds

Latest Headlines